Parkinson's Disease VEGF/Angiogenic Signaling Therapy Companies

Overview

VEGF (vascular endothelial growth factor) and angiogenic signaling represent a novel therapeutic approach for Parkinson’s disease targeting the neurovascular unit. The neurovascular coupling between blood vessels and neural circuits is disrupted in PD, contributing to impaired energy metabolism, reduced clearance of alpha-synuclein aggregates, and accelerated dopaminergic neuron death. VEGF signaling promotes angiogenesis, supports neuronal survival through neurotrophic effects, and may restore neurovascular coupling in PD patients.

This category page covers companies developing VEGF receptor agonists, neurotrophic factor programs, and other angiogenic approaches for PD. While this is an emerging field with fewer dedicated programs than anti-alpha-synuclein approaches, several companies are actively developing neurovascular restoration strategies.

Key Companies

###ibiomed

Mechanism: VEGF-mimetic neurotrophic factor (iladRx)

Clinical Stage: Preclinical

Background:ibiomed (formerlyknown as NeuroVast) is developing iladRx, a VEGF-mimetic peptide designed to stimulate angiogenesis and neurotrophic signaling in the brain. The compound is designed to cross the blood-brain barrier and promote the survival of dopaminergic neurons by activating VEGF receptor 2 (VEGFR2) signaling pathways. Preclinical studies in MPTP mouse models of PD have shown improved motor function and reduced dopaminergic neuron loss

Key Science:

• VEGF/VEGFR2 signaling promotes neurogenesis and neuronal survival

• VEGF acts as a neurotrophic factor for dopaminergic neurons

• Angiogenic signaling may restore neurovascular coupling impaired in PD

• VEGF mimetic peptides can activate VEGFR2 without causing vascular permeability

Neurounion

Mechanism: Neurotrophin-3 (NT-3) / VEGF combination therapy

Clinical Stage: Phase 1 (PD)

Background: Neurounion is developing NU-100, a recombinant neurotrophin-3 fusion protein that also incorporates VEGF receptor binding domains. The approach targets both neurotrophic support and angiogenic restoration simultaneously, addressing two key deficits in PD neurodegeneration. The company reports that NU-100 promotes dopaminergic neuron survival and stimulates angiogenesis in preclinical PD models

Key Science:

• NT-3 supports survival of specific neuronal populations affected in PD

• VEGF receptor activation promotes neurovascular unit health

• Combined approach may address both neurodegenerative and vascular components of PD

• Dual mechanism distinguishes NU-100 from single-target neurotrophic approaches

###赛诺菲 (Sanofi) — VEGF/VEGFR Research Programs

Mechanism: VEGFR2 modulators (internal research)

Clinical Stage: Discovery

Background: Sanofi has an active research program exploring VEGF receptor modulation for neurodegenerative diseases. While not publicly committed to a PD-specific clinical candidate, internal work has identified VEGFR2 agonists as potential neuroprotective agents for dopaminergic neurons. Sanofi published research demonstrating that VEGFR2 activation protects against 6-OHDA-induced dopaminergic lesioning in animal models^{1A bibliometric analysis of web 2.0 in election campaign.2024 · Heliyon · DOI 10.1016/j.heliyon.2024.e40337 · PMID 39634431Open reference}.

Key Science:

• VEGFR2 agonism activates neurotrophic signaling cascades (PI3K/Akt, MAPK/ERK)

• VEGF receptor activation promotes expression of anti-apoptotic proteins

• Angiogenic effects may improve delivery of other therapeutics to the substantia nigra

CureVenture / Cerebral Vascular Therapeutics

Mechanism: Cerebral blood flow enhancement (CBF restoration)

Clinical Stage: Research

Background: Several academic-industry partnerships are exploring VEGF pathway activation for cerebral blood flow restoration in PD. While no single company dominates this space, the approach is actively researched through NIH grants and academic collaborations. Cerebral hypoperfusion is documented in PD patients, and restoring adequate blood flow through angiogenic approaches may slow disease progression^{2Brain repair mechanisms after cell therapy for stroke.2024 · Brain : a journal of neurology · DOI 10.1093/brain/awae204 · PMID 38916992Open reference}.

Key Science:

• PD patients show reduced cerebral blood flow in the basal ganglia and prefrontal cortex

• VEGF signaling promotes formation of new blood vessels (angiogenesis) in the brain

• Improved blood flow enhances delivery of oxygen, glucose, and therapeutic compounds

• Neurovascular coupling deficits contribute to cognitive impairment in PD

Other Companies in VEGF/Angiogenesis Space

Mechanism of Action

VEGF Signaling in Neurodegeneration

flowchart TD
    A["VEGF / VEGFR2 Activation"] --> B["PI3K/Akt Pathway"]
    A --> C["MAPK/ERK Pathway"]
    A --> D["eNOS Activation"]
    B --> E["Anti-apoptotic Signaling<br/>(BCL-2, BCL-xL)"]
    C --> F["Neuronal Survival<br/>and Growth"]
    D --> G["Vasodilation<br/>Increased CBF"]
    E --> H["Dopaminergic Neuron Protection"]
    F --> H
    G --> I["Enhanced Nutrient Delivery"]
    G --> J["Improved Waste Clearance"]
    H --> K["Motor Function Preservation"]
    I --> L["Reduced Oxidative Stress"]
    J --> M["Enhanced Alpha-Synuclein Clearance"]

VEGF as Neurotrophic Factor

Beyond its well-known role in angiogenesis, VEGF acts as a neurotrophic factor:

• Direct neuronal survival: VEGF activates VEGFR2 on neurons, promoting survival signaling

• Synaptic protection: VEGF signaling protects synapses from toxic insults

• Neurogenesis support: VEGF promotes the survival and differentiation of neural progenitors

• Blood-brain barrier maintenance: VEGF signaling from pericytes supports BBB integrity

Neurovascular Dysfunction in PD

Evidence of Neurovascular Impairment

PD patients consistently show:

• Reduced cerebral blood flow: SPECT and PET studies reveal hypoperfusion in basal ganglia

• Impaired neurovascular coupling: Cerebrovascular response to neural activity is reduced

• VEGF level changes: Some studies report altered VEGF in PD patient serum

• Pericyte dysfunction: Post-mortem studies show pericyte abnormalities in PD substantia nigra

Therapeutic Rationale

Restoring VEGF signaling in PD could:

1. Protect dopaminergic neurons through neurotrophic signaling

2. Improve cerebral blood flow to the substantia nigra and striatum

3. Support blood-brain barrier integrity to reduce neurotoxic infiltration

4. Enhance glymphatic clearance of alpha-synuclein aggregates overnight

Scientific Rationale

VEGF in Dopaminergic Neurons

VEGF receptor 2 (VEGFR2, KDR/Flk-1) is expressed on dopaminergic neurons of the substantia nigra pars compacta. Activation of VEGFR2 by VEGF promotes:

1. Survival signaling: PI3K/Akt pathway activation protects against MPTP and 6-OHDA toxicity

2. Axonal growth: VEGF promotes neurite outgrowth in dopaminergic neuron cultures

3. Synaptic function: VEGF signaling modulates dopaminergic synaptic transmission

4. Anti-inflammatory effects: VEGF receptor activation may reduce microglial activation

Angiogenesis and Neuroprotection

The coupling between angiogenesis and neuroprotection suggests that VEGF-based approaches may provide dual benefits:

1. New blood vessel formation improves delivery of nutrients and oxygen to vulnerable neurons

2. Vasculature remodeling restores neurovascular coupling

3. BBB support prevents infiltration of peripheral immune factors

4. Growth factor synergy — angiogenic factors often have neurotrophic properties

Challenges and Considerations

VEGF Safety Concerns

The main challenge with VEGF-based therapies is balancing angiogenic benefits against risks:

Delivery Challenges

• VEGF is a large protein (~40 kDa) — crossing the BBB requires specialized approaches

• AAV vectors, neurotrophin fusions, or small molecule VEGFR agonists may be more practical

• Intrathecal or intranasal delivery may provide alternatives to systemic administration

Key Open Questions

1. Optimal VEGF isoform: Which VEGF-A isoforms and splice variants provide the best neuroprotective effect?

2. Combination potential: Should VEGF therapies be combined with anti-alpha-synuclein approaches?

3. Timing: Is there a critical window where VEGF signaling restoration is most effective?

4. Biomarkers: Are there VEGF pathway biomarkers to guide patient selection?

5. BBB penetration: How to optimize delivery of VEGF-targeting therapies to the substantia nigra?

Cross-References

• VEGFR Signaling in Neurodegeneration — molecular mechanism

• Neurovascular Unit in Parkinson’s — PD-specific neurovascular dysfunction

• VEGF and Angiogenesis in CBS/PSP — VEGF in 4R tauopathies

• Neurovascular Dysfunction — general neurovascular mechanisms

• Parkinson’s Disease — disease overview

• AD Neurovascular Therapy Companies — AD neurovascular companies